larazotide acetate
Sponsors
9 Meters Biopharma, Inc., Massachusetts General Hospital
Conditions
Celiac DiseaseCovid19HealthyLong COVIDLong COVID-19Multisystem Inflammatory Syndrome in ChildrenPost Acute COVID-19 SyndromePost Acute Sequelae of COVID-19
Phase 1
Phase 2
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
CompletedNCT00362856
Start: 2006-09-13End: 2007-03-06Updated: 2017-09-12
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
CompletedNCT00492960
Start: 2007-08-31End: 2009-03-31Updated: 2017-09-20
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
CompletedNCT00620451
Start: 2008-02-29End: 2009-12-31Updated: 2017-09-20
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
CompletedNCT00889473
Start: 2009-04-30End: 2010-04-30Updated: 2017-09-20
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
CompletedNCT01396213
Start: 2011-11-07End: 2013-08-20Updated: 2017-09-20
AT1001 for the Treatment of COVID-19 Related MIS-C
TerminatedNCT05022303
Start: 2021-10-01End: 2024-05-15Updated: 2024-06-13
AT1001 for the Treatment of Long COVID
CompletedNCT05747534
Start: 2023-05-31End: 2026-06-18Updated: 2026-08-18